NCT02252887 2025-07-25Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based TherapyMemorial Sloan Kettering Cancer CenterPhase 2 Completed45 enrolled